Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1

被引：0
|
作者：
van Wesemael, Tineke [1 ]
Borgers, Jessica [2 ]
Gelderman, Kyra [3 ]
Verdegaal, Els [4 ]
Korse, C. M. [5 ]
Welters, M. J. P. [6 ]
Kapiteijn, Ellen [7 ]
van Houdt, W. J. [2 ]
van der Burg, Sjoerd [6 ]
Toes, Rene [1 ]
Thienen, J. V. [2 ]
Haanen, John [2 ]
van der Woude, Diane [1 ]
机构：
[1] Leiden Univ Med Ctr, Leiden, Netherlands
[2] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Sanquin Diagnost Serv, Amsterdam, Netherlands
[4] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Netherlands Canc Inst, Dept Lab Med, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[6] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ Med Ctr, Dept Med Oncol, Leiden, Netherlands
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2510
引用
收藏
页码：4977 / 4979
页数：3
相关论文
共 50 条
  • [1] Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
    Borgers, Jessica S. W.
    van Wesemael, Tineke J.
    Gelderman, Kyra A.
    Rispens, Theo
    Verdegaal, Els M. E.
    Moes, Dirk J. A. R.
    Korse, Catharina M.
    Kapiteijn, Ellen
    Welters, Marij J. P.
    van der Burg, Sjoerd H.
    van Houdt, Winan J.
    van Thienen, Johannes, V
    Haanen, John B. A. G.
    van der Woude, Diane
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (06)
  • [2] Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
    John A. McCulloch
    Diwakar Davar
    Richard R. Rodrigues
    Jonathan H. Badger
    Jennifer R. Fang
    Alicia M. Cole
    Ascharya K. Balaji
    Marie Vetizou
    Stephanie M. Prescott
    Miriam R. Fernandes
    Raquel G. F. Costa
    Wuxing Yuan
    Rosalba Salcedo
    Erol Bahadiroglu
    Soumen Roy
    Richelle N. DeBlasio
    Robert M. Morrison
    Joe-Marc Chauvin
    Quanquan Ding
    Bochra Zidi
    Ava Lowin
    Saranya Chakka
    Wentao Gao
    Ornella Pagliano
    Scarlett J. Ernst
    Amy Rose
    Nolan K. Newman
    Andrey Morgun
    Hassane M. Zarour
    Giorgio Trinchieri
    Amiran K. Dzutsev
    Nature Medicine, 2022, 28 : 545 - 556
  • [3] Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
    McCulloch, John A.
    Davar, Diwakar
    Rodrigues, Richard R.
    Badger, Jonathan H.
    Fang, Jennifer R.
    Cole, Alicia M.
    Balaji, Ascharya K.
    Vetizou, Marie
    Prescott, Stephanie M.
    Fernandes, Miriam R.
    Costa, Raquel G. F.
    Yuan, Wuxing
    Salcedo, Rosalba
    Bahadiroglu, Erol
    Roy, Soumen
    DeBlasio, Richelle N.
    Morrison, Robert M.
    Chauvin, Joe-Marc
    Ding, Quanquan
    Zidi, Bochra
    Lowin, Ava
    Chakka, Saranya
    Gao, Wentao
    Pagliano, Ornella
    Ernst, Scarlett J.
    Rose, Amy
    Newman, Nolan K.
    Morgun, Andrey
    Zarour, Hassane M.
    Trinchieri, Giorgio
    Dzutsev, Amiran K.
    NATURE MEDICINE, 2022, 28 (03) : 545 - +
  • [4] RISK FACTORS OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH ANTI-PD-1 ANTIBODY PEMBROLIZUMAB
    Eun, Y.
    Kim, I. Y.
    Kim, H.
    Ahn, J. K.
    Park, E. -J.
    Hwang, J.
    Jeong, H.
    Chai, J. Y.
    Cha, H. -S.
    Koh, E. -M.
    Lee, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1205 - 1205
  • [5] Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
    Eun, Yeonghee
    Kim, In Young
    Sun, Jong-Mu
    Lee, Jeeyun
    Cha, Hoon-Suk
    Koh, Eun-Mi
    Kim, Hyungjin
    Lee, Jaejoon
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
    Yeonghee Eun
    In Young Kim
    Jong-Mu Sun
    Jeeyun Lee
    Hoon-Suk Cha
    Eun-Mi Koh
    Hyungjin Kim
    Jaejoon Lee
    Scientific Reports, 9
  • [7] Anti-PD-1 antibodies: immune-related adverse events and efficacy
    Reactions Weekly, 2019, 1739 (1) : 6 - 6
  • [8] Immune-related adverse events with resumed anti-PD-1 therapy
    Reactions Weekly, 2017, 1676 (1) : 4 - 4
  • [9] Autoantibody profiling for predictive biomarkers for immune-related adverse events and clinical benefit in rare tumors treated with anti-PD-1 therapy
    Derbala, Mohamed H.
    Hajjar, Joud
    Stephen, Bettzy
    Gurses, Serdar A.
    Kwiatkowski, Evan
    Budde, Petra
    Zucht, Hans-Dieter
    Brautigam, Manuel
    Schubert, Ann-Sophie
    Ahangarianabhari, Behnaz
    Rodriguez, Enedelia
    Gouda, Mohamed
    Castillo, Lilibeth
    Zarifa, Abdulrazzak
    How, Jeffrey A.
    Moyers, Justin T.
    Hong, David S.
    Meric-Bernstam, Funda
    Naing, Aung
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies
    Oya, Kazumasa
    Nakamura, Yoshiyuki
    Shen, Larina Tzu-Wei
    Ishizuki, Shoichiro
    Matsusaka, Satoshi
    Fujisawa, Yasuhiro
    JOURNAL OF DERMATOLOGY, 2024, 51 (06): : 807 - 815
12345